• Draganfly (DPRO) unveils Vital Intelligence Smart Vital Kiosk at the CES 2022 in Las Vegas
  • Smart Vital Kiosk can screen temperature, blood pressure, heart rate, respiratory rate, and oxygen saturation
  • Smart Vital Kiosk is part of Draganfly’s Vital Intelligence health and safety solution which is able to screen, detect, access and provide continuous action against the potential threat of infectious diseases, such as COVID-19
  • Draganfly (DPRO) is down 4.07 per cent at C$2.12 per share at 2:08 PM EST

Draganfly (DPRO) has unveiled the Vital Intelligence Smart Vital Kiosk at the CES 2022 in Las Vegas.

The Smart Vital Kiosk can screen body temperature, blood pressure, heart rate, respiratory rate, and oxygen saturation. The system does not register any personal data of the individual being screened.

The Smart Vital Kiosk is powered by Draganfly’s Vital Intelligence platform.

This Smart Vital system is part of Draganfly’s Vital Intelligence health and safety solution, which is able to screen, detect, access and provide continuous action against the potential threat of infectious diseases, such as COVID-19.

The Smart Vital Kiosk’s LCD screen is accessible, according to the Americans with Disabilities Act and its infrared thermal camera adheres to Food and Drug Administration’s guidelines.

Paul Mullen, Vice President of Vital Intelligence at Draganfly remarked on the Smart Vital Kiosk.

“We are committed to providing seamless and non-invasive solutions that allow organizations to host safe events and gatherings. Utilizing proprietary software built by Draganfly, the new Smart Vital Kiosk enables multi-dimensional screening of core vitals to provide real-time health insights in seconds.”

Draganfly is a corporation focusing on drone solutions, software and AI systems in regards to public safety, agriculture, and security.

Draganfly (DPRO) is down 4.07 per cent at C$2.12 per share at 2:08 PM EST.

More From The Market Online

Cancer fighter Theralase aims to turn lab wins into human trials

Theralase (TSXV:TLT) begins Good Laboratory Practice toxicology analysis of Rutherrin, its drug candidate to target and destroy cancer cells.

Restart Life Sciences serves up exponential revenue growth

Restart Life Sciences (CSE:HEAL) more than doubled revenue at stable profit margins in Q2 2026 amid several promising commercial activations.
The Market Online Video

NurExone Biologic progresses towards a new regenerative therapy and sets sights on a potential NASDAQ listing

NurExone CEO Dr. Lior Shaltiel discusses U.S. exosome manufacturing, Mexico expansion, ExoPTEN and plans for a potential U.S. listing.
The Market Online Video

Med-X targets global pest control market with Nature-Cide

Med-X CEO Matthew Mills discusses Nature-Cide, professional pest control partnerships, global expansion and the company’s planned Nasdaq listing.